Biotech · Public company · Vancouver, WA, US
CytoDyn Inc.
Ticker CYDY · SEC CIK 0001175680
Track this companyFree. Adds CytoDyn Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials161 recruiting or active
Pipeline programs26From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline26
- Optimized Background RegimenPhase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140Phase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140Phase 3 · HIV-1-infectionClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 (350 mg)Phase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 (525 mg)Phase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 (700 mg)Phase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 350Phase 3 · HIV-1-infectionClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 525Phase 3 · HIV-1-infectionClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 700Phase 3 · HIV-1-infectionClinicalTrials.gov · fetched Nov 12, 2026
- 200 mg pembrolizumabPhase 2 · Metastatic Colorectal Cancer (mCRC)ClinicalTrials.gov · fetched Nov 12, 2026
- 350 mg leronlimabPhase 2 · Metastatic Colorectal Cancer (mCRC)ClinicalTrials.gov · fetched Nov 12, 2026
- 350 mg leronlimabPhase 2 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- 525 mg leronlimabPhase 2 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- 700 mg leronlimabPhase 2 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- 700 mg leronlimabPhase 2 · Metastatic Colorectal Cancer (mCRC)ClinicalTrials.gov · fetched Nov 12, 2026
- AUC 5 CarboplatinPhase 2 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Historical dataPhase 2 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- LeronlimabPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Leronlimab (700mg)Phase 2 · Coronavirus Disease 2019ClinicalTrials.gov · fetched Nov 12, 2026
- leronlimab 350 mgPhase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- leronlimab 700 mgPhase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Maximum Tolerated Dose (MTD) of leronlimabPhase 2 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140Phase 2 · Graft Vs Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140 350mg weekly subcutaneous (SC) injection.Phase 2 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- PRO 140Phase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- leronlimab (PRO 140)TNBCClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 16, 2025ClinicalTrials.gov NCT06699836 · fetched Nov 12, 2026
- Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19PHASE2 · COMPLETED · started Mar 1, 2021ClinicalTrials.gov NCT04678830 · fetched Nov 12, 2026
- Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisPHASE2 · COMPLETED · started Dec 1, 2020ClinicalTrials.gov NCT04521114 · fetched Nov 12, 2026
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsPHASE2 · COMPLETED · started May 1, 2020ClinicalTrials.gov NCT04504942 · fetched Nov 12, 2026
- Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19PHASE2 · COMPLETED · started Apr 16, 2020ClinicalTrials.gov NCT04347239 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19PHASE2 · COMPLETED · started Apr 1, 2020ClinicalTrials.gov NCT04343651 · fetched Nov 12, 2026
- Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCPHASE1_PHASE2 · TERMINATED · started Apr 22, 2019ClinicalTrials.gov NCT03838367 · fetched Nov 12, 2026
- PRO 140 in Treatment-Experienced HIV-1 SubjectsPHASE2_PHASE3 · COMPLETED · started Jun 25, 2018ClinicalTrials.gov NCT03902522 · fetched Nov 12, 2026
- An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyPHASE2_PHASE3 · TERMINATED · started Aug 29, 2017ClinicalTrials.gov NCT05271370 · fetched Nov 12, 2026
- A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationPHASE2 · TERMINATED · started May 14, 2017ClinicalTrials.gov NCT02737306 · fetched Nov 12, 2026
- Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionPHASE2_PHASE3 · COMPLETED · started Dec 7, 2016ClinicalTrials.gov NCT02859961 · fetched Nov 12, 2026
- Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140PHASE2_PHASE3 · COMPLETED · started Oct 1, 2015ClinicalTrials.gov NCT02483078 · fetched Nov 12, 2026
- An Extension of Protocol PRO 140_CD01 StudyPHASE2 · TERMINATED · started Nov 18, 2014ClinicalTrials.gov NCT02355184 · fetched Nov 12, 2026
- Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionPHASE2 · COMPLETED · started Apr 16, 2014ClinicalTrials.gov NCT02175680 · fetched Nov 12, 2026
- Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersPHASE1 · COMPLETED · started Apr 16, 2004ClinicalTrials.gov NCT00110591 · fetched Nov 12, 2026
- An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)TEMPORARILY_NOT_AVAILABLEClinicalTrials.gov NCT07536815 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Oct 19, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Oct 14, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Aug 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- S-1 · S-1SEC EDGAR · filed Apr 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jan 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 1, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 21, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2025 · fetched Nov 12, 2026